PYPD
PolyPid
NASDAQ: PYPD · HEALTHCARE · BIOTECHNOLOGY
$4.53
+2.26% today
Updated 2026-04-29
Market cap
$84.54M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.09
Dividend yield
—
52W range
$2 – $5
Volume
0.1M
PolyPid (PYPD) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-5.6%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+61.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-4.8%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $-0.41 | -24.2% | $4.68 | $4.59 | -1.9% |
| 2025-11-12 | $-0.37 | +28.8% | $3.76 | $3.58 | -4.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.33 | $-0.41 | -24.2% | — | — |
| 2025-09-30 | $-0.52 | $-0.37 | +28.8% | — | — |
| 2025-06-30 | $-0.55 | $-0.78 | -41.8% | — | — |
| 2025-03-31 | $-0.82 | $-0.70 | +14.6% | — | — |
| 2024-12-31 | $-0.88 | $-1.07 | -21.6% | — | — |
| 2024-09-30 | $-1.00 | $-1.22 | -22.0% | — | — |
| 2024-06-30 | $-1.30 | $-1.25 | +3.8% | — | — |
| 2024-03-31 | $-1.41 | $-1.37 | +2.8% | — | — |
| 2023-12-31 | $-4.29 | $-3.84 | +10.5% | — | — |
| 2023-09-30 | $-4.43 | $-3.40 | +23.3% | — | — |
| 2023-06-30 | $-13.32 | $-10.80 | +18.9% | — | — |
| 2023-03-31 | $-4.80 | $-8.40 | -75.0% | — | — |
Frequently asked questions
Has PolyPid beaten earnings estimates?
PolyPid has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -5.6% over the last 4 quarters.
How does PYPD stock react to earnings?
PYPD stock has moved an average of -3.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.